financetom
Business
financetom
/
Business
/
Urban Outfitters Can Mitigate Tariff Headwinds, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Urban Outfitters Can Mitigate Tariff Headwinds, UBS Says
Sep 2, 2025 12:22 PM

03:12 PM EDT, 09/02/2025 (MT Newswires) -- Urban Outfitters ( URBN ) is positioned to mitigate more of the tariff headwinds than previously expected by shifting the country of origin for goods, negotiating with vendors, adjusting transportation modes, and raising prices selectively, UBS Securities said.

The company reported fiscal Q2 net income of $1.58 per diluted share, compared with $1.24 a year earlier and ahead of the $1.48 expected by analysts. Net sales for the period ended July 31 rose to $1.50 billion from $1.35 billion a year earlier, topping the $1.48 billion consensus.

The brokerage said in a Monday note that the company's fiscal Q2 beat was helped by lower markdowns and rent leverage.

The firm raised its gross margin estimates for Q3 and Q4 by 20 and 80 basis points, respectively, and lifted Q3 sales and adjusted EPS forecasts to $1.46 billion and $1.21, respectively.

For 2025, UBS now models sales of $6.04 billion and adjusted EPS of $5.15, while its longer-term EPS forecasts for 2026 and 2027 were each increased by $0.05 on a stronger margin outlook.

The brokerage also pointed to mid-single digit comparable sales growth modeled for Anthropologie, Free People, and Urban Outfitters brands.

The firm said it continues to expect the stock to perform in line with peers over the next 12 months.

UBS raised its price target to $79 from $78 and reiterated its neutral rating on the company's stock.

Price: 66.75, Change: -0.32, Percent Change: -0.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ionis Pharmaceuticals' Q2 loss Narrows as Revenue Increases
Ionis Pharmaceuticals' Q2 loss Narrows as Revenue Increases
Aug 1, 2024
09:06 AM EDT, 08/01/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) reported a Q2 loss Thursday of $0.45 per diluted share, narrowing from a loss of $0.60 a year earlier. Analysts polled by Capital IQ expected a loss of $0.91. Revenue for the quarter ended June 30 was $225 million, up from $188 million a year earlier. Analysts surveyed...
Kellanova raises 2024 forecasts on stable snacks demand in North America
Kellanova raises 2024 forecasts on stable snacks demand in North America
Aug 1, 2024
(Reuters) - Kellanova ( K ) raised its annual organic sales and profit forecasts on Thursday as consumers opted for its breakfast cereals and ready-to-eat snacks such as Pringles despite higher prices. Shares of the company were up 4% before the bell, after it also beat Wall Street expectations for second-quarter results. The company, which previously made up Kellogg's (...
EU seeking feedback on draft antitrust guidelines on exclusionary abuses
EU seeking feedback on draft antitrust guidelines on exclusionary abuses
Aug 1, 2024
BRUSSELS (Reuters) - The European Commission said on Thursday it had launched a public consultation inviting all interested parties to comment on draft guidelines on exclusionary abuses of dominance, which include predatory pricing, margin squeeze, exclusive dealing and refusal to supply. In a statement, the Commission said those guidelines will help increase legal certainty to the benefit of consumers, and...
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
Aug 1, 2024
On Wednesday, ALX Oncology Holdings Inc ( ALXO ). released topline data from its Phase 2 ASPEN-06 clinical trial. ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The ASPEN-06 study is testing a new...
Copyright 2023-2026 - www.financetom.com All Rights Reserved